Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 316 of 6351
-
Inhaled drug combo aims to boost lung cancer treatment before surgery
Disease control PausedBackground: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Surgery to remove the tumors is the standard treatment for people diagnosed with early stages of NSCLC. Despite complete rem…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
New universal flu vaccine enters human testing
Vaccine Recruiting nowBackground: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pande…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 10, 2026 03:00 UTC
-
Brain zaps and yoga poses: new hope for Veterans' back pain?
Symptom relief Not yet recruitingThe objectives of this VA Merit application are to demonstrate efficacy of combined intermittent theta burst (iTBS) and yoga (iTBS+yoga) intervention on improving pain, function, analgesic use, self-efficacy, quality of life and well-being among Veterans with chronic low back pai…
Phase 3 • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Gene test could tailor chemo doses for rare cancer
Disease control Recruiting nowBackground: High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, neck, and head. One drug (belinostat), combined with 2 other drugs (etoposide and cisplatin), is approved to treat HGNEC. Bu…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Engineered immune cells take aim at deadly lung cancer
Disease control Not yet recruitingBackground: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that develops anywhere other than the lungs. EPNEC is also deadly. B7-H3 is a protein often found in SCLC and EPNEC tumor cell…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Personalized stem cell transplant aims to beat inherited blood cancers
Disease control Not yet recruitingBackground: Some blood cancers can be caused by germline variants (changes) in a person s RUNX1 gene. Germline variants are genetic inherited changes a person is born with. Stem cell transplants are used to treat many diseases including blood cancers. Stem cell transplantation f…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
New pill aims to halt lung scarring in thousands
Disease control Not yet recruitingThis study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are at risk of developing progressive pulmonary fibros…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New vaccine combo aims to halt prostate cancer growth without surgery
Disease control Not yet recruitingBackground: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is managed with active monitoring. However, 35% of men with this cancer will need treatment within 5 years because of tumor …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Experimental cell therapy takes on tough leukemia
Disease control Not yet recruitingBackground: B-cell acute lymphoblastic leukemia (B-ALL) is a type of blood cancer. Some people with B-ALL have a gene mutation that makes the disease hard to treat. The mutation causes cancer cells to make too much of a protein called thymic stromal lymphopoietin receptor (TSLPR…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
New pill-chemo combo takes on hard-to-treat cancers
Disease control Not yet recruitingBackground: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States. Survival rates for these cancers are lower than 50% if…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Immune-Boosting drug and vaccine aim to fight returning prostate cancer
Disease control Not yet recruitingBackground: Biochemically recurrent prostate cancer (BCR) occurs when prostate-specific antigen (PSA) levels in the blood rise after surgery or radiation. BCR affects 30,000 to 50,000 men each year. Researchers want to know if a drug (N-803) alone or combined with a vaccine (ETB…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Experimental drug KER-065 aims to slow muscle decline in duchenne muscular dystrophy
Disease control Not yet recruitingThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KER-065 administered to adult and pediatric ambulatory and nonambulatory male participants with Duchenne Muscular Dystrophy (DMD) on stable background …
Phase 2 • Sponsor: Keros Therapeutics, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Smartphone app may boost parenting skills for child outbursts
Disease control Not yet recruitingBackground: Pediatric disruptive behavior disorders (DBDs) are characterized by severe irritability, anger, and temper outbursts. The primary way to treat children with DBDs is parent management training (PMT). PMT teaches parents how to reward desired behaviors and not to rewar…
Sponsor: National Institute of Mental Health (NIMH) • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Can a nerve-zapping ear device supercharge exercise for neck pain?
Disease control Not yet recruitingThis randomized controlled trial aims to investigate whether the timing of transcutaneous auricular vagus nerve stimulation (taVNS) relative to exercise influences clinical and autonomic outcomes in individuals with chronic neck pain. Participants will be randomly allocated to o…
Sponsor: Kutahya Health Sciences University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Zapping the brain to calm an overactive bladder?
Symptom relief Not yet recruitingNeurogenic overactive bladder (nOAB) is a common and distressing sequela following stroke, significantly impairing quality of life and imposing a substantial financial burden. Existing pharmacological options often present adverse effects, while standard non-pharmacological treat…
Sponsor: The Hong Kong Polytechnic University • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC
-
Can online rehab match In-Person training for MS?
Symptom relief Not yet recruitingThis randomized controlled study was planned to compare the effects of delivering the same exercise content face-to-face and through telerehabilitation in individuals diagnosed with multiple sclerosis. All participants will receive circuit training for 8 weeks. The program will c…
Sponsor: Istanbul University - Cerrahpasa • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
Which Second-Line drug works best for axial spondyloarthritis? a trial aims to find out
Disease control Not yet recruitingThe purpose of this study is to determine the feasibility of conducting a pragmatic trial of IL-17i versus JAKi in adults with axial spondyloarthritis (axSpA) who have failed at least one tumor necrosis factor-alpha inhibitor (TNFi), to estimate the effectiveness of IL-17i versus…
Phase 4 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Could a social media app help heal the emotional scars of cancer?
Symptom relief Not yet recruitingThe main purpose of this Keep Social randomized controlled trial is to examine the effectiveness of our social connectedness intervention to improve social and emotional well-being among young adults with cancer. The investigators will conduct a randomized controlled trial with a…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
A Parent's voice may soothe NICU babies, and a trial puts it to the test
Symptom relief Not yet recruitingThe purpose of this study is to investigate the impact of a caregiver-initiated reading intervention to their infant, in the Neonatal Intensive Care Unit (NICU), on the caregiver-infant dyad, both during hospitalization and following discharge. The specific aims are: Aim 1: To e…
Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
Could a plant oil spray tame chronic sinusitis with fewer steroids?
Disease control Not yet recruitingChronic rhinosinusitis (CRS) is a persistent inflammatory disease of the nose and sinuses, defined by the presence of symptoms for at least 12 weeks. Medical treatment of CRS is mainly based on topical therapies aimed at controlling mucosal inflammation and improving naso-sinus c…
Sponsor: Liaquat University of Medical & Health Sciences • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC